Compare Illumina, Inc. (ILMN) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Nasdaq Inc — how do they compare? Illumina, Inc. trades at $191.04 (market cap $27.94B), while Nasdaq Inc trades at $90.58 (market cap $51.96B). The key difference: Nasdaq Inc is the larger of the two by market cap, and Nasdaq Inc pays a 1.22% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | NDAQ | |
|---|---|---|
Market Cap | $27.94B | $51.96B |
Sector | Health | Financials |
52-Week High | $194.33 | $100.98 |
52-Week Low | $91.00 | $76.85 |
Enterprise Value | $29.33B | $59.02B |
Dividend Yield | — | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Nasdaq (NDAQ) trades at $92.00, up 0.39% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $105.60. Recent earnings beats and strong profitability margins, including a net income margin of 23.03%, highlight fundamental strength. The company continues to expand its non-trading businesses and execute strategic initiatives, as noted in recent financial media coverage.
The outlook for NDAQ is positive, driven by consistent earnings performance and strategic growth in market infrastructure. Key risks include market volatility sensitivity and high valuation multiples. Investors should weigh the robust analyst support against potential macroeconomic headwinds affecting exchange volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
